#USA #San Diego #Phanes Therapeutics #KEYTRUDA #Spevatamig

Phanes Therapeutics Expands Clinical Collaboration with Merck

Phanes Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing innovative drug discovery in oncology, recently announced a significant expansion of its clinical trial collaboration and supply agreement with Merck. This partnership aims to evaluate the effectiveness of spevatamig—an innovative bispecific antibody—in combination with Merck's renowned anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), alongside chemotherapy as a first-line treatment for biliary tract cancer (BTC).

Overview of Spevatamig and Its Significance

Spevatamig is a unique anti-CLDN18.2/CD47 bispecific antibody that acts as an innate immunity enhancer, supporting a promising new class of immuno-oncology agents. It is presently advancing through Phase 2 studies targeting various gastrointestinal cancers. The recent expansion of the collaboration will allow for a deeper investigation into this combination therapy's potential advantages for patients suffering from biliary tract cancer, a highly aggressive form of cancer characterized by limited treatment options.

Ming Wang, PhD, MBA and CEO of Phanes, expressed enthusiasm about extending the partnership, highlighting BTC's devastating impact and the urgent need for effective therapies. He stated, “This reflects our vision of leveraging the combination of innate immunity enhancers (I2Es) with other therapies to target hard-to-treat cancers.”

The Mechanism Behind the Combination Therapy

The unique approach of using spevatamig in concert with KEYTRUDA® and chemotherapy is pivotal. Spevatamig functions as an I2E, enhancing the body's immune response by activating key components such as macrophages and dendritic cells. This mechanism aims to empower the immune system to identify and eliminate cancer cells, particularly in what are known as cold tumors, which frequently show limited responsiveness to conventional immune checkpoint inhibitors (ICIs).

As more patients are treated with KEYTRUDA, combining it with emerging therapies like spevatamig may significantly improve treatment outcomes in cancers traditionally regarded as challenging to manage.

Phanes Therapeutics: Pioneers in Oncology Innovation

Phanes is committed to initiating groundbreaking research in oncology. The company is currently conducting multiple Phase 2 clinical trials featuring not only spevatamig but also its other promising molecules, peluntamig and mavrostobart. Both spevatamig and peluntamig have been recognized as first-in-class bispecific antibodies, receiving orphan drug designations from the FDA for innovative cancer treatments.

Phanes’s proprietary technology platforms, including PACbody®, SPECpair®, and ATACCbody®, fuel their ambitious pipeline, unlocking novel biologics that focus on critical medical needs in cancer care.

Further solidifying its commitment, the company maintains a transparent relationship with stakeholders and is open to inquiries regarding potential partnerships and media communications.

For individuals interested in Phanes Therapeutics and their innovative approaches to combating cancer, more information is available at www.phanesthera.com.

In conclusion, Phanes Therapeutics' expanded collaboration with Merck represents a crucial step forward in innovative cancer treatment, impacting future research direction and offering hope to those diagnosed with biliary tract cancer.